Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to ...

EGFR inhibitors like AstraZeneca's Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of treatment is often reduced by resistance mutations. Now ...

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...

Patients on Tagrisso had less than half the risk of progression or death compared with patients on Tarceva or Iressa: the median PFS was 18.9 months for patients on Tagrisso vs.10.2 months for ...

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

AstraZeneca’s Tagrisso (osimertinib) has been approved by the European Commission (EC) to treat a new subset of lung cancer patients. The epidermal growth factor receptor (EGFR)-tyrosine kinase ...

AstraZeneca AZN announced that its blockbuster cancer drug, Tagrisso (osimertinib), has been approved in the EU for expanded use in non-small cell lung cancer (NSCLC). The eligible patient ...

Chinese regulators have accepted HUTCHMED's (NASDAQ:HCM) application for priority review for the drug combination Orpathys and Tagrisso in the treatment of certain patients with EGFR-positive non ...